OBJECTIVES: The aim of this study was to assess the effectiveness and safety of febuxostat for chronic gout. METHODS: We retrospectively review patients with diagnosis of gout (ICD-9 250) concomitant with febuxostat during Jun 2012 to Dec 2013 in Changhua Christian Hospital. Patients with prescription of febuxostat less than 30 days were excluded. We collect the data of patient age, sex and analyzed the progression of renal function (eGFR) and uric acid. Prescribed Daily Dose (PDD) of febuxostat was calculated. Hospital-based spontaneous reporting systems databases were survey for the febuxostat adverse reaction reporting. RESULTS: A total of 151 patients were included with mean age 68.3±14.4 years. There were 40 female and 111 male ( F:M ; 1:2.8).The average duration of prescription was 148.0±88.5 days. Prescribed Daily Dose (PDD) of febuxostat was 44mg. The uric acid was decrease from 9.1±1.9 to 6.6±2.7mg/dL. The eGFR was increased from 33.5±23.5 to 34.9±25.1 ml/min/1.73m at the baseline. In subgroup analysis, 42 patients with the duration of prescription 31-90 days (average 55.8±15.6 days ), 59 patients with 91-180 days(average 127.6±25.6 days), 50 patients with > 181 days (average 249.6±68.77 days), the uric acid derement was 2.3±2.8 mg/dL, 2.6±2.9 mg/dL and 2.8±2.1 mg/dL respectively. A total of 6 cases reported as mild adverse reaction, 4 cases reported as skin reaction. Other reactions reported was chills and insomnia.The incidence of ADR was 3.97%.(6/151) CONCLUSIONS: Febuxostat is an effective urate-lowering agent. We found a trend that the longer Febuxostat use, the more uric acid decline. The safety of febuxostat was well tolerated since the adverse reaction reported was mild. The total 6 cases adverse reaction reported were occurred in eGFR <60 ml/min/1.73m